Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Carcinoma in Situ × 1-phenyl-3,3-dimethyltriazene × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4 Carcinoma, Basal Cell 4 Pleural Diseases 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Sezary Syndrome 1 Salivary Gland Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Pain 1 Non-Muscle Invasive Bladder Neoplasms 1 Mycosis Fungoides 1 Mesothelioma, Malignant 1 Lymphoma, T-Cell, Cutaneous 1 Leukoplakia, Oral 1 Esthesioneuroblastoma, Olfactory 1 Carcinoma, Transitional Cell 1 Carcinoma in Situ 1 Basal Cell Nevus Syndrome 1 Adenocarcinoma, Follicular 1 Adenocarcinoma of Lung 1

Interventions

enfortumab vedotin 1 durvalumab 1 cemiplimab 1 advexin 1 Tomography, X-Ray Computed 1 Surveys and Questionnaires 1 Nivolumab 1 Magnetic Resonance Imaging 1 Histamine Antagonists 1 Electrocardiography 1 Diphenhydramine 1 Cystoscopy 1 Cholecalciferol 1 Acetaminophen 1 1-phenyl-3,3-dimethyltriazene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02698293 2022-11-22

PDT Plus Vitamin D3 for Anal Dysplasia

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn

Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon ⚡